Discover six hemophilia companies developing new treatments for the genetic bleeding disorder, from gene therapies to RNAi therapies.

We unpack the full scope of the U.S. budget cuts, from canceled clinical trials and stalled drug approvals to mass layoffs ...

The antibody discovery landscape is at a turning point. As the demand for more effective and targeted therapeutics grows to tackle challenging targets, traditional methods—focused on binding rather ...

Find out how genome sequencing has emerged and what the future holds for one of biotech's most important tools.

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Biotech companies have always been global at their core. From running clinical trials across continents to delivering therapies internationally, success in these industries also depends on crossing ...